Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: February 22, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 2376 miles
University of Virginia
Charlottesville,VA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03473639

Entinostat & Capecitabine for Stage II, Stage III or Metastatic HER2 Negative Breast Cancer

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy Scientific Title

Purpose
To study the safety and effects (good and bad) of the combination of entinostat and capecitabine (Xeloda®).
Who is this for?
People with metastatic (stage IV) breast cancer or stage II or stage III HER2 negative breast cancer who have had neoadjuvant chemotherapy that included a taxane or anthracycline and have had breast cancer surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Entinostat, by mouth, once a week, for 6 months</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, twice a day for 2 out of every 3 weeks, for 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">For stage IV patients, treatment is received for as long as benefit is shown</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Entinostat is an investigational type of targeted therapy called an HDAC inhibitor. </li> <li class="seamTextUnorderedListItem">Xeloda is a chemotherapy drug used to treat metastatic breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03473639' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/capecitabine.aspx' target='_blank'>Chemocare: Capecitabine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/entinostat' target='_blank'>NCI Drug Dictionary: Entinostat</a> </li></ul>
See more